Thermo Fisher Scientific and Symphogen, an affiliate of and the antibody centre of excellence within the international pharmaceutical company, Servier, have extended a collaboration to deliver innovative characterisation and quality control workflows for the simplified analysis of complex therapeutic proteins to advance biopharmaceutical discovery and development.
Since the collaboration was established in 2018, Symphogen has been utilising the analytical capabilities offered by Thermo Fisher Scientific to develop, test and routinely implement platform workflows for intact and native mass analysis of therapeutic monoclonal antibody (mAb) mixtures.
“Through our collaboration with Symphogen, we can provide the biopharmaceutical industry with proven characterisation methods that can be translated into transferable, routine, compliance-ready solutions to boost drug discovery and development,” said Eric Grumbach, Director, biopharma/pharma, chromatography and mass spectrometry, Thermo Fisher Scientific. “By continuing to invest in this relationship, we demonstrate our commitment to offer solutions designed to tackle today’s most pressing biopharmaceutical challenges.”
Dan Bach Kristensen, Principal Investigator, Symphogen, said, “Over the past two years, the advanced characterisation and lead selection studies of several hundred mAb samples enabled by the Q Exactive Plus Orbitrap LC-MS/MS system has allowed us to simplify our analytical strategies, ultimately accelerating our pipeline. Extending our collaboration with Thermo Fisher is the natural way forward to continue driving innovation in the discovery and development of highly differentiated cancer therapeutics.”
Image credit: ThisIsEngineering RAEng
